Get the Stockscreener App
3.77
3.08%
-0.12
After Hours:
3.72
-0.05
-1.33%
Alto Neuroscience Inc stock is traded at $3.77, with a volume of 101.60K.
It is down -3.08% in the last 24 hours and up +22.80% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$3.89
Open:
$3.88
24h Volume:
101.60K
Relative Volume:
0.53
Market Cap:
$102.08M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-1.7486
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-2.84%
1M Performance:
+22.80%
6M Performance:
+6.20%
1Y Performance:
-73.28%
1-Day Range:
$3.69
$3.94
1-Week Range:
$3.41
$3.95
52-Week Range:
$1.60
$15.04
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.77 | 105.33M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
ANRO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - GlobeNewswire Inc.
Alto Neuroscience, Inc. (ANRO) LawsuitInvestors Urged to Contact Levi & Korsinsky Before September 19, 2025 - ACCESS Newswire
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - Business Wire
Alto Neuroscience announces robust replication of EEG biomarker - MarketScreener
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia - Business Wire
Alto Neuroscience Inc. stock daily chart insightsQuarterly Portfolio Summary & High Accuracy Buy Signal Tips - Newser
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT - GlobeNewswire
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Class Action Filed Against Alto Neuroscience, Inc. (ANRO) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Alto Neuroscience, Inc. (NYSE: ANRO) Investor Alert: Deadline in Lawsuit on September 19, 2025 - openPR.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain OfficersANRO - PR Newswire
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Contact The Gross Law Firm by September 19, 2025 Deadline to Join Class Action Against Alto Neuroscience, Inc.(ANRO) - PR Newswire
ANRO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the - GlobeNewswire
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025ANRO - FinancialContent
What’s next for Alto Neuroscience Inc. stock priceWeekly Trade Report & Safe Capital Growth Trade Ideas - Newser
Chart overlay techniques for tracking Alto Neuroscience Inc.Weekly Investment Recap & Weekly High Conviction Ideas - Newser
Historical volatility pattern of Alto Neuroscience Inc. visualizedWeekly Risk Report & AI Powered Trade Plan Recommendations - Newser
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers – ANRO - FinancialContent
Securities Litigation Risks and Investor Implications in Biotech: Focusing on Alto Neuroscience - AInvest
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - MarketScreener
Is Alto Neuroscience Inc. being accumulated by smart money2025 Pullback Review & Community Consensus Trade Signals - خودرو بانک
Can Alto Neuroscience Inc. expand into new marketsTrade Exit Report & Free Expert Verified Stock Movement Alerts - خودرو بانک
What are analysts’ price targets for Alto Neuroscience Inc.2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - خودرو بانک
Nuveen LLC Takes $302,000 Position in Alto Neuroscience, Inc. $ANRO - Defense World
Does Alto Neuroscience Inc. have pricing power2025 Trading Recap & Reliable Price Breakout Signals - خودرو بانک
Alto Neuroscience, Inc. Investors: Please contact the - GlobeNewswire
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) InvestorsLead Plaintiff Deadline on September 19, 2025 - ACCESS Newswire
Will Alto Neuroscience Inc. outperform tech stocksJuly 2025 Action & Free High Accuracy Swing Entry Alerts - خودرو بانک
Regression analysis insights on Alto Neuroscience Inc. performanceJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - Newser
Does Alto Neuroscience Inc. stock reflect fundamentalsJuly 2025 Highlights & Weekly High Return Opportunities - خودرو بانک
ANRO DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Alto Neuroscience, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 19 Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Lawsuit Filed Against Alto Neuroscience, Inc. (ANRO)Recover LossesContact Levi & Korsinsky Before September 19, 2025 - ACCESS Newswire
Alto Neuroscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your RightsANRO - WV News
Lost Money on Alto Neuroscience, Inc. (ANRO)? Join Class - GlobeNewswire
Using Python tools to backtest Alto Neuroscience Inc. strategiesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - Newser
Published on: 2025-09-04 06:28:13 - خودرو بانک
Technical signs of recovery in Alto Neuroscience Inc.Breakout Watch & Weekly High Return Stock Forecasts - Newser
What are Alto Neuroscience Inc.’s recent SEC filings showingMarket Performance Recap & Long-Term Safe Investment Plans - خودرو بانک
Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 19, 2025 Deadline to file Lead Plaintiff Motion. - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - Morningstar
Published on: 2025-09-03 09:03:31 - Newser
About Us - FinancialContent
ANRO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Backtesting results for Alto Neuroscience Inc. trading strategies2025 Retail Activity & AI Driven Price Forecasts - Newser
Should I buy Alto Neuroscience Inc. stock nowMarket Volume Report & Capital Protection Trade Alerts - خودرو بانک
Is Alto Neuroscience Inc.’s growth already priced inJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - khodrobank.com
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):